Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. - Wikidata - awgldk - TriplyDB

Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.

Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.

http://www.wikidata.org/entity/Q37598156

about

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Dealing with the spiralling price of medicines: issues and solutions.Estimated costs of production and potential prices for the WHO Essential Medicines List.

P2860

Q41526451-7EE8CA33-FEE9-4E88-8FC3-CB3D447B4327 Q50080930-2DF77261-2056-4D21-9270-08522CB6799E Q53699577-D70046C0-0BC7-480B-BE23-FA93968CE412

P2860

Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.

http://www.wikidata.org/entity/Q37598156

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Estimated generic prices of ca ...... d: a cost estimation analysis.

@en

Estimated generic prices of ca ...... d: a cost estimation analysis.

@nl

type

label

Estimated generic prices of ca ...... d: a cost estimation analysis.

@en

Estimated generic prices of ca ...... d: a cost estimation analysis.

@nl

prefLabel

Estimated generic prices of ca ...... d: a cost estimation analysis.

@en

Estimated generic prices of ca ...... d: a cost estimation analysis.

@nl

P1433

Q37598156-8C831820-C424-4A1D-A1D9-3D4504572912

P1476

Q37598156-BA25F869-3FE9-4F13-BD90-DA9127E27E10

P2093

Q37598156-0190A7D8-F859-45FD-8A5D-64D2745A3BE1

Q37598156-55A3C90D-26C8-480B-95D8-74E2936B1D13

Q37598156-772D034D-BDAB-4C72-9790-0A72806AAB81

Q37598156-B8E31A09-68A9-4397-84CA-1769D7A419A5

Q37598156-E32F892C-FCCA-4B18-861C-C430BFD6BEDC

P2860

Q37598156-035FFC44-DF18-49D7-8FBB-77E7C4BEB989

Q37598156-0A367CBC-9C90-4C5D-BBFC-65EBD992ECCA

Q37598156-11967CD7-5021-48C9-AF46-D2DDF25CF4A7

Q37598156-1A238350-5C8E-44BF-A3FF-846C0FD2D067

Q37598156-1AAFC65A-3EF3-45D9-9DBF-3F67F7736F18

Q37598156-21B17B6D-34A7-4F47-BE46-08B3F73DF3AD

Q37598156-3E3C97D5-6851-4E70-8A3F-2CE432B195A2

Q37598156-4238DBB5-0949-4647-840C-763FA7F79D89

Q37598156-5B463860-12F8-4E48-B122-F7017D7AC4AC

Q37598156-67538F8B-3D13-49E0-8EF5-8FD850B01271

P304

Q37598156-D84435FD-EED0-4B35-B11F-F19F8A706815

P31

Q37598156-A32D6E06-C87F-4B66-9D27-F78F0217199C

P356

Q37598156-0CAB9135-DB40-42D3-AAF1-08D2514522D1

P433

Q37598156-703A0343-FBB8-45FA-BE2F-4DB36CD3C532

P478

Q37598156-AC410E4E-CEDB-4E39-85DF-64D91869FFB3

P50

Q37598156-8CC462AF-3058-4224-9C24-63AC98B780E1

P577

Q37598156-34455922-6352-46B5-A3FA-2F3628CDE01A

P698

Q37598156-9E691137-1202-48DA-BCDE-5353C09AB189

P932

Q37598156-6CE79EF6-D4B9-4E38-AF9B-03CC8FB8D874

P356

BMJOPEN-2016-011965

P1433

P1476

Estimated generic prices of ca ...... nd: a cost estimation analysis

@en

P2093

Andrew Hill

http://www.w3.org/2001/XMLSchema#string

Christopher Redd

http://www.w3.org/2001/XMLSchema#string

Isabelle Erbacher

http://www.w3.org/2001/XMLSchema#string

Jonathan Meldrum

http://www.w3.org/2001/XMLSchema#string

Ryo Harada

http://www.w3.org/2001/XMLSchema#string

P2860

A clinician's guide to biosimilars in oncology

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014.

P304

e011965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJOPEN-2016-011965

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Dzintars Gotham

P577

2017-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28110283

http://www.w3.org/2001/XMLSchema#string

P932

5253524

http://www.w3.org/2001/XMLSchema#string